Clinical Trial Update: The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial is evaluating the combination of LMV-12 with Osimertinib for non-small cell lung cancer, including tumors with RET mutations, MET amp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• LMV-12
• Osimertinib (osimertinib)

Snippet

Sponsor: Hunan Province Tumor Hospital | Conditions: Non Small Cell Lung Cancer, RET Gene Mutation | Phase 1, Phase 2 | Status: RECRUITING